Three-Year Clinical Outcomes of Everolimus-Eluting Stents From the Post-Marketing Surveillance Study of Cobalt-Chromium Everolimus-Eluting Stent (XIENCE V/PROMUS) in Japan-Reference-Cited by-同舟云学术

Three-Year Clinical Outcomes of Everolimus-Eluting Stents From the Post-Marketing Surveillance Study of Cobalt-Chromium Everolimus-Eluting Stent (XIENCE V/PROMUS) in Japan

Published:2016 Issue:4 Volume:80 Page:906-912
ISSN:1346-9843
Container-title:Circulation Journal
language:en
Short-container-title:Circ J

Author:

Aoki Jiro¹,Kozuma Ken²,Awata Masaki³,Nanasato Mamoru⁴,Shiode Nobuo⁵,Tanabe Kengo¹,Yamaguchi Junichi⁶,Kusano Hajime⁷,Nie Hong⁷,Kimura Takeshi⁸,

Affiliation:

1. Division of Cardiology, Mitsui Memorial Hospital

2. Department of Cardiology, Teikyo University Hospital

3. Department of Advanced Cardiovascular Therapeutics, Osaka University Graduate School of Medicine

4. Cardiovascular Center, Nagoya Daini Red Cross Hospital

5. Division of Cardiology, Akane Foundation Tsuchiya General Hospital

6. Department of Cardiology, Tokyo Women’s Medical University

7. Abbott Vascular

8. Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine

Publisher

Japanese Circulation Society

Subject

Cardiology and Cardiovascular Medicine,General Medicine

Link

https://www.jstage.jst.go.jp/article/circj/80/4/80_CJ-15-1181/_pdf

Reference30 articles.

1. 1. Daemen J, Wenaweser P, Tsuchida K, Abrecht L, Vaina S, Morger C, et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: Data from a large two-institutional cohort study. Lancet 2007; 369: 667–678.

2. 2. Kimura T, Morimoto T, Nakagawa Y, Kawai K, Miyazaki S, Muramatsu T, et al. Very late stent thrombosis and late target lesion revascularization after sirolimus-eluting stent implantation: Five-year outcome of the j-Cypher Registry. Circulation 2012; 125: 584–591.

3. 3. Palmerini T, Biondi-Zoccai G, Della Riva D, Stettler C, Sangiorgi D, D’Ascenzo F, et al. Stent thrombosis with drug-eluting and bare-metal stents: Evidence from a comprehensive network meta-analysis. Lancet 2012; 379: 1393–1402.

4. 4. Baber U, Mehran R, Sharma SK, Brar S, Yu J, Suh JW, et al. Impact of the everolimus-eluting stent on stent thrombosis: A meta-analysis of 13 randomized trials. J Am Coll Cardiol 2011; 58: 1569–1577.

5. 5. Navarese EP, Tandjung K, Claessen B, Andreotti F, Kowalewski M, Kandzari DE, et al. Safety and efficacy outcomes of first and second generation durable polymer drug eluting stents and biodegradable polymer biolimus eluting stents in clinical practice: Comprehensive network meta-analysis. BMJ 2013; 347: f6530, doi:10.1136/bmj.f6530.

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tudor-SN exacerbates pathological vascular remodeling by promoting the polyubiquitination of PTEN via NEDD4-1;Journal of Biomedical Science;2024-09-05

2. Comparison of the “Late Catch-Up” Phenomenon Between BuMA Supreme and XIENCE Stents Through Serial Optical Coherence Tomography at 1–2 Month and 2 Year Follow-Ups: A Multicenter Study;Cardiovascular Innovations and Applications;2024

3. Bleeding risk factors and real-world antithrombotic therapies in elderly patients with atrial fibrillation undergoing percutaneous coronary intervention: a retrospective study;Journal of Pharmaceutical Health Care and Sciences;2023-12-12

4. Midterm safety and efficacy of elective drug-coated balloon angioplasty in comparison to drug-eluting stents for unrestrictive de novo coronary lesions: A single center retrospective study;Journal of Cardiology;2023-06

5. Drug-Eluting Stents: Technical and Clinical Progress;Biomimetics;2023-02-09